Jagsonpal Pharmaceuticals has entered into a definitive agreement for the acquisition of 85% equity stake in Aequitas Healthcare (Aequitas), a Mumbai-based pharmaceutical company primarily focused on sale and distribution of pharmaceutical products to hospitals. The proposed acquisition marks the company’s strategic entry into the hospital segment and is aligned with the company's long-term vision of strengthening its presence in India’s growing healthcare ecosystem.
The total consideration for 85% stake would be Rs 20.8 crore, which shall be funded from internal accruals of the company. The current Directors of Aequitas shall retain 15% stake and shall continue to be associated with the business. The transaction is subject to the fulfilment of customary closing conditions, and expected to be concluded by July 15, 2026.
Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.00 |
| Dr. Reddys Labs. | 1344.25 |
| Cipla | 1457.20 |
| Zydus Lifesciences | 1109.45 |
| Lupin | 2399.30 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: